← Back to Search

Symptom Monitoring System for Childhood Cancer (SyMon-SAYS Trial)

N/A
Recruiting
Led By Jin-Shei Lai, PhD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have a hematology/oncologic diagnosis (including a brain tumor)
Patients must be between 8 and 17 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to week 8; and from week 9 to week 16
Awards & highlights

SyMon-SAYS Trial Summary

This trial plans to develop a symptom monitoring system that uses technology to report symptoms experienced by children with cancer to their parents and health care providers.

Who is the study for?
This trial is for children aged 8-17 with cancer, including brain tumors, who are currently receiving treatment or have completed therapy within the last 6 months. They must be able to understand and use English to give consent and interact with a symptom monitoring system on an electronic device.Check my eligibility
What is being tested?
The study is testing SyMon-SAYS, a technology-based system designed to track and report symptoms of young cancer survivors. It aims to improve communication between children living with cancer, their parents, and healthcare providers.See study design
What are the potential side effects?
Since this intervention involves information technology rather than medication, traditional side effects are not applicable. However, there may be issues related to usability or stress associated with regular symptom reporting.

SyMon-SAYS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a blood cancer or brain tumor.
Select...
I am between 8 and 17 years old.

SyMon-SAYS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to week 8; and from week 9 to week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to week 8; and from week 9 to week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adherence to intervention
Health related quality of life
Overall symptom burden
+2 more

SyMon-SAYS Trial Design

2Treatment groups
Experimental Treatment
Group I: SyMon-SAYS Waitlist Control (Group B)Experimental Treatment1 Intervention
The waitlist control group participants (Group B) will receive their usual care during weeks 1-8 and will receive the SyMon-SAYS intervention every week during weeks 9-16.
Group II: SyMon-SAYS Intervention (Group A)Experimental Treatment1 Intervention
Group A participants will receive the SyMon-SAYS intervention every week for 16 weeks.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,589 Previous Clinical Trials
916,926 Total Patients Enrolled
Ann & Robert H Lurie Children's Hospital of ChicagoOTHER
258 Previous Clinical Trials
5,188,930 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,667 Previous Clinical Trials
40,925,882 Total Patients Enrolled

Media Library

Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS) Clinical Trial Eligibility Overview. Trial Name: NCT04789720 — N/A
Cancer Research Study Groups: SyMon-SAYS Intervention (Group A), SyMon-SAYS Waitlist Control (Group B)
Cancer Clinical Trial 2023: Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS) Highlights & Side Effects. Trial Name: NCT04789720 — N/A
Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04789720 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being accepted into this experiment?

"Affirmative. Clinicaltrials.gov maintains records that this trial is still enrolling patients, having first been posted on April 1st 2021 and last updated June 17th 2021. The study needs to recruit 200 people from a single medical site."

Answered by AI

Who is eligible to partake in this investigation?

"To be a viable candidate for this research, prospective participants must have cancer and age between 8 to 17. This study is currently looking for up to 200 individuals."

Answered by AI

Is this experiment in need of additional participants at the moment?

"This trial, which was initially posted on April 1st 2021 is still searching for participants. The most recent update to the study took place on June 17th of this year."

Answered by AI

Is admission to this clinical trial restricted to those aged seventy or younger?

"As per the given criteria, the lower bound for qualification is 8 years old and no participant can be older than 17."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Using Information Technology to Improve Outcomes for Children Living With Cancer
Jin-Shei Lai 2021. "Using Information Technology to Improve Outcomes for Children Living With Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04789720.
~36 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top